eFFECTOR is developing a novel class of small molecule drugs to selectively regulate translation (protein synthesis) with an initial emphasis on cancer. The company has multiple molecules in clinical trials and a partnership with Pfizer. Kevan Shokat, ex-Intellikine (a portfolio company that Abingworth exited successfully in 2012), is one of the scientific founders. Brian Gallagher is Chairman of the board.
Location | San Diego, California |
CEO | Steve Worland |
Partner | Brian Gallagher |
Website | www.effector.com |